Transplantation of genetically engineered mesenchymal stem cells improves cardiac function in rats with myocardial infarction

Benefit of a novel nonviral vector, cationized dextran

Jun Ichiro Jo, Noritoshi Nagaya, Yoshinori Miyahara, Masaharu Kataoka, Mariko Harada-Shiba, Kenji Kangawa, Yasuhiko Tabata

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

It is expected that mesenchymal stem cells (MSCs) will be a cell source for cardiac reconstruction because of their differentiation potential and ability to supply growth factors. However, poor viability at the transplanted site often hinders the therapeutic potential of MSCs. Here, in a trial designed to address this problem, a non-viral carrier of cationized polysaccharide is introduced for genetic engineering of MSCs. Spermine-introduced dextran of cationized polysaccharide (spermine-dextran) was internalized into MSCs by way of a sugar-recognizable receptor to enhance the expression level of plasmid deoxyribonucleic acid (DNA). When genetically engineered by the spermine-dextran complex with plasmid DNA of adrenomedullin (AM), MSCs secreted a large amount of AM, an anti-apoptotic and angiogenic peptide. Transplantation of AM gene-engineered MSCs improved cardiac function after myocardial infarction significantly more than MSCs alone. Thus, this genetic engineering technology using the non-viral spermine-dextran is a promising strategy to improve MSC therapy for ischemic heart disease.

Original languageEnglish
Pages (from-to)313-322
Number of pages10
JournalTissue Engineering
Volume13
Issue number2
DOIs
Publication statusPublished - 2007 Feb 1
Externally publishedYes

Fingerprint

Dextran
Stem cells
Rats
Genetic engineering
Polysaccharides
DNA
Engineering technology
Sugars
Peptides
Genes

ASJC Scopus subject areas

  • Engineering(all)

Cite this

Transplantation of genetically engineered mesenchymal stem cells improves cardiac function in rats with myocardial infarction : Benefit of a novel nonviral vector, cationized dextran. / Jo, Jun Ichiro; Nagaya, Noritoshi; Miyahara, Yoshinori; Kataoka, Masaharu; Harada-Shiba, Mariko; Kangawa, Kenji; Tabata, Yasuhiko.

In: Tissue Engineering, Vol. 13, No. 2, 01.02.2007, p. 313-322.

Research output: Contribution to journalArticle

Jo, Jun Ichiro ; Nagaya, Noritoshi ; Miyahara, Yoshinori ; Kataoka, Masaharu ; Harada-Shiba, Mariko ; Kangawa, Kenji ; Tabata, Yasuhiko. / Transplantation of genetically engineered mesenchymal stem cells improves cardiac function in rats with myocardial infarction : Benefit of a novel nonviral vector, cationized dextran. In: Tissue Engineering. 2007 ; Vol. 13, No. 2. pp. 313-322.
@article{4fdd6cd015f34ffcb47a4382fd91e638,
title = "Transplantation of genetically engineered mesenchymal stem cells improves cardiac function in rats with myocardial infarction: Benefit of a novel nonviral vector, cationized dextran",
abstract = "It is expected that mesenchymal stem cells (MSCs) will be a cell source for cardiac reconstruction because of their differentiation potential and ability to supply growth factors. However, poor viability at the transplanted site often hinders the therapeutic potential of MSCs. Here, in a trial designed to address this problem, a non-viral carrier of cationized polysaccharide is introduced for genetic engineering of MSCs. Spermine-introduced dextran of cationized polysaccharide (spermine-dextran) was internalized into MSCs by way of a sugar-recognizable receptor to enhance the expression level of plasmid deoxyribonucleic acid (DNA). When genetically engineered by the spermine-dextran complex with plasmid DNA of adrenomedullin (AM), MSCs secreted a large amount of AM, an anti-apoptotic and angiogenic peptide. Transplantation of AM gene-engineered MSCs improved cardiac function after myocardial infarction significantly more than MSCs alone. Thus, this genetic engineering technology using the non-viral spermine-dextran is a promising strategy to improve MSC therapy for ischemic heart disease.",
author = "Jo, {Jun Ichiro} and Noritoshi Nagaya and Yoshinori Miyahara and Masaharu Kataoka and Mariko Harada-Shiba and Kenji Kangawa and Yasuhiko Tabata",
year = "2007",
month = "2",
day = "1",
doi = "10.1089/ten.2006.0133",
language = "English",
volume = "13",
pages = "313--322",
journal = "Tissue Engineering",
issn = "1076-3279",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Transplantation of genetically engineered mesenchymal stem cells improves cardiac function in rats with myocardial infarction

T2 - Benefit of a novel nonviral vector, cationized dextran

AU - Jo, Jun Ichiro

AU - Nagaya, Noritoshi

AU - Miyahara, Yoshinori

AU - Kataoka, Masaharu

AU - Harada-Shiba, Mariko

AU - Kangawa, Kenji

AU - Tabata, Yasuhiko

PY - 2007/2/1

Y1 - 2007/2/1

N2 - It is expected that mesenchymal stem cells (MSCs) will be a cell source for cardiac reconstruction because of their differentiation potential and ability to supply growth factors. However, poor viability at the transplanted site often hinders the therapeutic potential of MSCs. Here, in a trial designed to address this problem, a non-viral carrier of cationized polysaccharide is introduced for genetic engineering of MSCs. Spermine-introduced dextran of cationized polysaccharide (spermine-dextran) was internalized into MSCs by way of a sugar-recognizable receptor to enhance the expression level of plasmid deoxyribonucleic acid (DNA). When genetically engineered by the spermine-dextran complex with plasmid DNA of adrenomedullin (AM), MSCs secreted a large amount of AM, an anti-apoptotic and angiogenic peptide. Transplantation of AM gene-engineered MSCs improved cardiac function after myocardial infarction significantly more than MSCs alone. Thus, this genetic engineering technology using the non-viral spermine-dextran is a promising strategy to improve MSC therapy for ischemic heart disease.

AB - It is expected that mesenchymal stem cells (MSCs) will be a cell source for cardiac reconstruction because of their differentiation potential and ability to supply growth factors. However, poor viability at the transplanted site often hinders the therapeutic potential of MSCs. Here, in a trial designed to address this problem, a non-viral carrier of cationized polysaccharide is introduced for genetic engineering of MSCs. Spermine-introduced dextran of cationized polysaccharide (spermine-dextran) was internalized into MSCs by way of a sugar-recognizable receptor to enhance the expression level of plasmid deoxyribonucleic acid (DNA). When genetically engineered by the spermine-dextran complex with plasmid DNA of adrenomedullin (AM), MSCs secreted a large amount of AM, an anti-apoptotic and angiogenic peptide. Transplantation of AM gene-engineered MSCs improved cardiac function after myocardial infarction significantly more than MSCs alone. Thus, this genetic engineering technology using the non-viral spermine-dextran is a promising strategy to improve MSC therapy for ischemic heart disease.

UR - http://www.scopus.com/inward/record.url?scp=33847073124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847073124&partnerID=8YFLogxK

U2 - 10.1089/ten.2006.0133

DO - 10.1089/ten.2006.0133

M3 - Article

VL - 13

SP - 313

EP - 322

JO - Tissue Engineering

JF - Tissue Engineering

SN - 1076-3279

IS - 2

ER -